{{Rsnum
|rsid=12233719
|Gene=UGT2B7
|Chromosome=4
|position=69096731
|Orientation=plus
|GMAF=0.03949
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=UGT2B7
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 100.0 | 0.0 | 0.0
| HCB | 75.0 | 25.0 | 0.0
| JPT | 72.7 | 25.0 | 2.3
| YRI | 100.0 | 0.0 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 75.0 | 25.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12233719
|Name_s=UGT2B7*3; UGT2B7:A71S; UGT2B7:211G>T
|Gene_s=UGT2B7
|Feature=Exon/NonSyn
|Evidence=PubMed ID:17978490
|Annotation=Greatly reduced the efficiency of metabolism of carvedilol.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145129
}}

{{GET Evidence
|gene=UGT2B7
|aa_change=Ala71Ser
|aa_change_short=A71S
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12233719
|overall_frequency_n=2
|overall_frequency_d=10754
|overall_frequency=0.000185977
|n_genomes=1
|n_genomes_annotated=0
|n_haplomes=1
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|nblosum100=-1
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}